Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| NTRA | +69.64% | −5.40% | −4.26% | −5.29% | +43.75% | +87.49% | +96.05% | +809.29% | +1,036.35% |
| ES-GENOME | +64.37% | −2.58% | +0.99% | −7.42% | +25.05% | +60.84% | +56.72% | +64.10% | +34.22% |
| TGENOME | +58.85% | −2.78% | +1.41% | −5.52% | +24.00% | +54.88% | +54.22% | +68.14% | +41.02% |
| SCBGENOME(SSFE) | +69.56% | −3.06% | +1.33% | −6.29% | +25.66% | +60.45% | +62.13% | +81.46% | +44.62% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes NTRA: money market or bond funds, or no holdings data yet
| ES-GENOME | SCBGENOME(SSFE) | |
|---|---|---|
| Held by both | ||
| ARK Genomic Revolution ETF | 34.51% | 80.05% |
| iShares Genomics Immunology and Healthcare ETF | 0.40% | 23.05% |
| Only in ES-GENOME | ||
| ARK Genomic Revolution UCITS ETF | 70.29% | N/A |
30 Dec 2025 → 3 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| SCBGENOME(SSFE) | +69.56% | 42.54% | 1.64 |
| ES-GENOME | +64.37% | 42.32% | 1.52 |
| TGENOME | +58.85% | 40.23% | 1.46 |
| NTRA | +69.64% | 52.59% | 1.32 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | NTRA | ES-GENOME | TGENOME | SCBGENOME(SSFE) |
|---|---|---|---|---|
Fund details | ||||
| Fund size | N/A | 225 million | 1,372 million | 3.35 million |
| Inception date | N/A | 23 Mar 2021 | 13 Jan 2021 | 20 Aug 2021 |
| Master fund | N/A | กองทุนที่ลงทุนหลายกอง (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | กองทุนที่ลงทุนหลายกอง (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | กองทุน ARK Genomic Revolution ETF |
| Dividend policy | N/A | Does not pay | Does not pay | Pays |
Risk and currency hedging | ||||
| Risk level | N/A | 7 | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | N/A | 79.06% | 84.93% | 57.68% |
Minimum purchase and redemption | ||||
| First purchase | N/A | 1 THB | 1,000 THB | 1 THB |
| Subsequent purchase | N/A | 1 THB | 1,000 THB | 1 THB |
| Redemption (amount) | N/A | 1 THB | No minimum | No minimum |
| Redemption (units) | N/A | 1 units | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | No minimum | No minimum |
| Balance (units) | N/A | No minimum | No minimum | No minimum |
Order cut-off and redemption payment | ||||
| Buy before | N/A | 15:30 | 15:30 | 15:30 |
| Redeem before | N/A | 15:30 | 15:30 | 15:30 |
| Redemption paid | N/A | T+4 | T+3 | T+4 |
